TrialBMC cancer2011

EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer.

Karen-Lise G Spindler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.